As HCW Biologics prepares for its Q1 2026 earnings call, analysts are modeling a consensus net loss of $0.44 per share on zero core revenue, with the stock currently trading at $1.13 against a bullish $22.00 average price target. Investors are zeroed in on the company's clinical progress for HCW9302, an IL-2 fusion protein for alopecia areata, following the recent dosing of Phase 1 patient cohorts.
A recent $6.5 million licensing agreement with Trimmune has significantly bolstered the company's balance sheet, though liquidity remains a primary concern under recent going-concern warnings. Market participants are seeking clarity on the timeline for Phase 1 human data readouts and updates regarding the company’s Nasdaq listing status as it manages high R&D overhead.